Evaluating the effectiveness of infliximab on perianal fistulizing Crohn’s disease by magnetic resonance imaging

Xiaohan Yan¹,†, Mingming Zhu¹,†, Qi Feng²,†, Yunqi Yan², Jiangchen Peng¹, Xitao Xu¹, Antao Xu¹ and Zhihua Ran¹,*

¹Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health; Shanghai Inflammatory Bowel Disease Research Center; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China and ²Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

*Corresponding author. Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health; Shanghai Inflammatory Bowel Disease Research Center; Renji Hospital, School of Medicine, Shanghai Jiao Tong University; 145 Middle Shandong Road, Shanghai 200001, China. Tel: +86-13801868827; Email: zhihuaran@vip.163.com

†These authors contributed equally to this work.

Abstract

Background and aim: Data on the radiologic evaluation of perianal fistulizing Crohn’s disease (PFCD) naïve to anti-tumor necrosis factor therapy are scarce, especially in Asian populations. We assessed the effectiveness of infliximab (IFX) on PFCD and explored predictors of ‘deep remission’ based on clinical and radiologic assessments.

Methods: Patients with Crohn’s disease and active anal fistulas attending our care center for IFX therapy were prospectively enrolled. Each patient underwent clinical examination according to the Fistula Drainage Assessment Index, endoscopy for assessment of Crohn’s Disease Activity Index (CDAI) and Perianal Crohn’s Disease Activity Index (PCDAI), magnetic resonance imaging (MRI) to determine Van Assche score and Ng score, and laboratory tests up to 2 weeks prior to the start of and up to 2 weeks after the sixth IFX therapy (Week 32).

Results: Among 38 patients treated with IFX, 52.6% achieved clinical remission based on the Fistula Drainage Assessment Index and 42.1% achieved deep remission based on Ng score. Van Assche score (from 14.5±4.26 to 7.36±7.53), CDAI (from 170±92 to 71±69) and PCDAI (from 7.45±2.65 to 2.44±3.20) decreased significantly after six IFX treatments. The only predictor of deep remission was simple fistula (P=0.004, odds ratio = 3.802, 95% confidence interval: 1.541–9.383).

Conclusions: IFX has been shown to have appreciable effectiveness in Chinese patients with PFCD. MRI is the gold standard for evaluating PFCD, but Van Assche score has some limitations.

Key words: Crohn’s disease; perianal fistula; magnetic resonance imaging; infliximab
Introduction
Perianal fistulizing Crohn’s disease (PFCD) has a serious impact on quality of life and mental health [1]. It is always indicative of a more aggressive and refractory disease phenotype [2]. A population-based study found that the incidence of perianal fistula in patients with Crohn’s disease (CD) is 21–23% and that the cumulative incidences of the condition at 1, 5, 10 and 20 years are 12, 15, 21 and 26%, respectively [3–5]. Large prospective and retrospective studies have shown that two-thirds of patients with PFCD experience relapses; thus, the treatment of PFCD is challenging [6, 7].

Medical treatments for PFCD include antibiotics, immuno-suppressants (ISs) and anti-tumor necrosis factor (TNF) agents, and surgical treatments include seton, fistulotomy, fistulectomy, advancement flap, fecal diversion and proctectomy [8–11]. Nearly 40% of PFCD patients underwent proctectomy before the clinical application of biologic agents [12]. Biologic agents such as infliximab (IFX) have brought new hope to PFCD patients: after continuous treatment for 1 year, one-third of patients maintain clinical remission [13]. Personalized treatments are required based on magnetic resonance imaging (MRI) findings [14]. Pelvic enhancement MRI is the first choice for evaluating PFCD and monitoring the effects of treatment [10]. When used in combination with examination under anesthesia, its specificity and sensitivity are increased [11].

Exploring predictors of the need for different therapies is an important guide for treatment selection for PFCD. Fistula healing based on MRI evaluation is always later than that based on clinical evaluation. Therefore, in the Second European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease [15], it was proposed that a clinical examination should be combined with MRI as the basis of an effective clinical evaluation. Most previous studies have evaluated treatment efficacy based on clinical evaluation rather than endoscopic or radiologic findings. However, the assessment of treatment efficacy should be based on ‘deep remission’ (the absence of anal canal ulcers and presence of healing on MRI in association with clinical remission) or the combination of clinical assessment and objective radiologic and endoscopic evaluations. T2-weighted imaging (T2WI) and fat-suppression sequences are the gold standard for the MRI evaluation of fistulas [16]. Imaging-based scoring, although not yet widely used in clinical practice, can reflect disease activity.

In this study, we describe the clinical and radiologic courses of PFCD treated by IFX, evaluate the efficacy of IFX for the condition and explore the predictors of deep remission.

Patients and methods
Patients and protocol
Between September 2015 and May 2017, all consecutive patients diagnosed with CD and at least one draining fistula who attended our center for IFX therapy were prospectively enrolled. CD diagnosis was based on a combination of clinical, serologic, endoscopic and pathologic examinations. The diagnosis of anal fistula was based on examination under anesthesia and MRI. IFX therapy consisted of induction therapy (5 mg/kg at Weeks 0, 2 and 6) followed by maintenance therapy (5 mg/kg every 8 weeks). The exclusion criteria included age less than 18 years, pregnancy and unwillingness to undergo IFX therapy or follow-up at our center for more than 6 months.

The data retrieved from medical records included: age; sex; date of diagnosis; smoking history; family history of inflammatory bowel disease (IBD); disease distribution according to the Montreal classification; treatments (antibiotics, setons, immunomodulators) before IFX therapy; type of fistula; concomitant treatment; adverse events; need for surgical treatment; and early IFX withdrawal because of adverse events or lack of efficacy.

Up to 2 weeks prior to the start of IFX therapy and up to 2 weeks after the sixth IFX therapy (Week 32), each patient underwent clinical assessment of their fistulas according to the Fistula Drainage Assessment Index, MRI to determine Van Assche score, Ng score, main fistula length, endoscopy, assessment of Crohn’s Disease Activity Index (CDAI) and Perianal Crohn’s Disease Activity Index (PCDAI) and laboratory tests for the following parameters: white blood-cell count; neutrophil count; hemoglobin concentration (HB); hematocrit; platelet count (PLT); C-reactive protein concentration (CRP); erythrocyte sedimentation rate (ESR); and Albumin concentration (ALB). Concurrent therapies for CD, including antibiotics and ISs, were permitted. Seton placement was allowed before IFX therapy. All participants of this study provided written informed consent. The study protocol was approved by the Research Ethics Committee of Renji Hospital (School of Medicine, Shanghai Jiao Tong University, Shanghai, China).

Evaluation of effectiveness
CDAI was applied to evaluate the disease activity of CD in terms of general well-being, abdominal pain, abdominal mass, diarrhea, the need for diphenoxylate/atropine or opiates for diarrhea, hematocrit, weight and complications [17]. PCDAI was assessed on the basis of five clinical symptoms: discharge; restriction of activities; restriction of sexual activity; type of perianal disease; and degree of induration [18]. Each section was rated from 0–5 according to severity.

Clinical evaluation was performed according to the Fistula Drainage Assessment Index. The definition of ‘clinical remission’ was the absence of any draining fistulas and any drainage episodes self-reported by the patient in two successive evaluations under gentle finger compression. ‘Clinical response’ meant reducing the number of draining fistulas by half or more from baseline under gentle finger compression at the clinical evaluation. In all other circumstances, patients were considered ‘non-responders’ [19]. All clinical examinations were performed by the same senior physician specialized in IBD dedicated to each patient. We no longer assess the Van Assche score of the MRIs of healed fistulas according to Ng score: the Van Assche scores of these MRIs were regarded as zero.

A senior radiologist specialized in gastrointestinal radiology with more than 10 years of experience evaluated the MRIs by calculating the main fistula length and diameter, abscess volume, proctitis, Van Assche score and Ng score. The radiologist used the same standardized report for the initial and follow-up MRIs and was blinded to each patient’s medical history and clinical outcome. The Van Assche score included six items, with higher scores indicating severe disease (ranging from 0–22): complexity of the fistula tracts; location relative to the sphincters; extent; hyperintensity on T2WI; presence of abscesses; and rectal wall involvement [20]. We used the predetermined MRI definitions proposed by Ng et al. [21, 22] to classify the radiologic findings (Table 1).

The need for surgery, severe secondary effects requiring discontinuation of medical therapy and voluntary discontinuation of treatment were considered treatment failures.
Table 1. Ng Score for perianal Crohn’s disease severity

| Terms       | Definition                                                                 |
|-------------|----------------------------------------------------------------------------|
| Healed      | Absence of high-signal tracks on fat-saturated T2-weighted sequences       |
| Partial response | Reduction in the number of fistula tracts and/or draining cavities and/or a reduction in the volume of inflammation of 10% or more |
| Unchanged   | Similar number of tracts and volume of inflammation                        |
| Deterioration | Development of new tracts or collections, or an increase in the size or number of any previous cavities or fistula tracts |

MRI parameters

MRI examinations were performed using a Philips Achieva 3.0-T scanner with a cardiac phased-array coil (Philips Medical Systems, Amsterdam, The Netherlands) and a Philips Ingenia 3-T scanner with a torso phased-array coil (Philips Medical Systems). Patients did not receive any bowel preparation. All patients underwent examination in the supine position. The MRI sequence protocol is presented in Supplementary Table 1. The intravenous injection was a mean dose of 15–20 ml gadolinium-diethylenetriamine pentaaetic-acid (Magnevist®, Schering AG, Berlin, Germany) and the scan delay was 60 s. The oblique coronal plane was placed parallel to and the oblique transverse plane was placed perpendicular to the long axis of the anal canal. Patients with contraindications to MRI, such as severe claustrophobia, pacemakers or metallic implants, were excluded.

Statistical analysis

Continuous variables are presented as means and standard deviation, and categorical variables as percentages and 95% confidence intervals (CIs). Comparison of patients was conducted using the χ² test for categorical variables and the Student’s t-test for continuous variables. The χ²-statistic was used to assess the correlation between clinical response and radiologic indices. Predictors of deep remission were assessed using multiple logistic regression analysis. Models of logistic regression were performed. The results were considered statistically significant if a P-value of <0.05. We used SPSS 18.0 (SPSS Inc., Chicago, IL, USA) for all statistical analyses.

Results

Patient characteristics

A total of 38 patients (26.3% women) with a mean age of 28.5 ± 8.2 years scheduled for IFX therapy were prospectively enrolled. Of them, 68.4% had complex fistulas and 5.3% had anorecto-vaginal fistulas. Among them, 8 patients were receiving a combination of IFX and azathioprine (AZA), whereas 30 patients were receiving IFX alone. The baseline characteristics of this study population are presented in Table 2.

Clinical and radiologic responses

Four patients discontinued because of adverse effects or subjective reluctance, whereas 20 (52.6%) were in clinical remission, 9 (23.7%) exhibited a clinical response and 5 (13.2%) were non-responders after six IFX therapies. CDAI and PCDAI decreased significantly from 170 ± 92 and 7.45 ± 2.65 at baseline to 71 ± 69 and 2.44 ± 3.2 after six IFX therapies, respectively (both P < 0.05).

According to Ng score, 16 (42.1%) of the patients achieved deep remission, 11 (28.9%) exhibited a partial response, 4 (10.5%) remained unchanged and 3 (7.9%) deteriorated (Table 3). The healing rates of patients receiving IFX therapy alone and those receiving AZA + IFX were 40% (12/30) and 50% (4/8), respectively. Van Assche score decreased significantly from 14.50 ± 4.26 at baseline to 7.36 ± 7.53 after six IFX therapies (Figure 1). The changes in patient ratios for the six components of the Van Assche score are shown in detail in Figure 2.

The changes in serologic findings are shown in Supplementary Table 2. ESR (from 18.6 ± 19.4 to 11 ± 12.3 mm/h, P < 0.05), CRP (from 9.59 ± 11.3 to 4.24 ± 8.09 mg/L, P < 0.05) and PLT (from 286 ± 88 × 10⁸ to [260 ± 91] × 10⁸, P < 0.05) decreased significantly between baseline and after six IFX therapies, whereas ALB (from 39.8 ± 6.2 to 43.7 ± 5.16 g/L, P < 0.05) and HB (from 125 ± 21.8 to 134 ± 23 g/L, P < 0.05) increased significantly.

Correlation between clinical and radiologic responses

Clinical examination according to the Fistula Drainage Assessment Index and MRIs were performed in each patient. Sixteen of the 20 patients (80%) who were in clinical remission exhibited healed fistula tracts on MRI and six of the nine

Table 2. Baseline characteristics of 38 patients with perianal fistulizing Crohn’s disease

| Variables IFX patients (n = 38) |
|----------------------------------|
| Sex                              |
| Male                             | 28 (73.7%) |
| Female                           | 10 (26.3%) |
| Age, years                       | 28.5 ± 8.2 |
| Smokers                          | 2 (5.3%) |
| IBD family history               | 0 (0%)    |
| CD disease location              | 13 (34.2%)|
| L1 (ileal)                       | 3 (7.9%)  |
| L2 (Colonic)                     | 22 (57.9%)|
| L3 (ileocolonic)                 |            |
| Duration, years                  | 1.95 ± 3.01|
| Fistula location                 |            |
| Superficial                      | 1 (2.6%)  |
| Intersphincteric                 | 19 (50%)  |
| Transphincteric                  | 14 (36.8%)|
| Suprasphincteric                 | 2 (5.3%)  |
| Extrasphincteric                 | 2 (5.3%)  |
| Fistula type                     |            |
| Simple fistula                   | 12 (31.6%)|
| Complex fistula                  | 26 (68.4%)|
| Anorecto-vaginal fistula         | 2 (5.3%)  |
| Proctitis                        | 20 (52.6%)|
| Abscess                          | 20 (52.6%)|
| Previous surgery                 |            |
| Drainage techniques              | 10 (26.3%)|
| Seton or fistulotomy             | 9 (23.7%) |
| Fistulectomy                     | 5 (13.2%) |
| Segmental bowel resection        | 2 (5.3%)  |
| Treatment                        |            |
| Infliximab                       | 30 (78.9%)|
| Infliximab + azathioprine        | 8 (21.1%) |
| Time between initial and follow-up MRI | 6 infliximab therapy |
Table 3. Clinical and radiologic evaluation of infliximab (IFX) efficacy

| Outcomes                                           | IFX patients (n = 38) |
|----------------------------------------------------|-----------------------|
| **Discontinued**                                   | 4 (10.5%)             |
| **Clinical evaluation**                            |                       |
| **Fistula Drainage Assessment Index**              |                       |
| Clinical remission                                 | 20 (52.6%)            |
| Clinical response                                  | 9 (23.7%)             |
| Non-response                                       | 5 (13.2%)             |
| **Crohn’s Disease Activity Index**                 |                       |
| Baseline                                           | 170 ± 92              |
| Follow-up                                          | 71 ± 69*              |
| **Perianal Crohn’s Disease Activity Index**        |                       |
| Baseline                                           | 7.45 ± 2.65           |
| Follow-up                                          | 2.44 ± 3.20*          |
| **Radiologic evaluation**                          |                       |
| Ng score                                           |                       |
| Healed                                             | 16 (42.1%)            |
| Partial response                                   | 11 (28.9%)            |
| Unchanged                                          | 4 (10.5%)             |
| Deterioration                                      | 3 (7.9%)              |
| Healing rate of complex fistulas                   | 8/26 (30.8%)          |
| **Van Assche score**                               |                       |
| Baseline                                           | 14.5 ± 4.26           |
| Follow-up                                          | 7.36 ± 7.53*          |
| **Maximum fistula length, mm**                     |                       |
| Baseline                                           | 41.4 ± 20.7           |
| Follow-up                                          | 17.2 ± 23.1*          |
| **Maximum fistula diameter, mm**                   |                       |
| Baseline                                           | 3.39 ± 1.81           |
| Follow-up                                          | 1.18 ± 1.58*          |

*P < 0.05.

Predictors of deep remission

In a univariate analysis, deep remission was significantly associated with low initial Van Assche score (12.6 ± 4.3 vs 15.9 ± 3.7, P = 0.015), absence of proctitis (P = 0.047) and simple fistula (P = 0.002), but showed no relationship with sex, age, duration of disease, smoking history, surgery history, absence of abscesses, combinatorial treatment with AZA, CD disease location, main fistula length on initial MRI, main fistula diameter on initial MRI, the five components of Van Assche score except fistula type, initial CDAI, initial PCDAI or initial laboratory findings (all P > 0.05). In a multivariate analysis, deep remission was only significantly associated with simple fistula (odds ratio 3.802, 95% CI: 1.541–9.383, P = 0.004).

Safety of IFX therapy

Four patients were considered to have experienced treatment failure. One patient discontinued because of pre-excitation syndrome after the first IFX therapy, one because of hepatic postemia at the fourth IFX therapy, one because of pulmonary infection at the fifth IFX therapy and one postponed the sixth IFX therapy because of upper respiratory tract infection then discontinued for being reluctant to follow IFX therapy. In addition, two patients presented minor adverse effects (dermatitis) that did not require cessation of the therapy.

Discussion

Anti-TNF therapies have revolutionized the management of PFCD. Several randomized controlled trials have proven their efficacy at achieving and maintaining remission of PFCD [23, 24]. However, few studies have focused on deep remission as the therapeutic outcome of interest and, to the best of our knowledge, there are no studies involving Asian populations. In this study, we prospectively examined the clinical and radiologic evaluation of IFX therapy for PFCD. 52.6% of our patients receiving IFX therapy achieved clinical remission, whereas 42.1% exhibited deep remission.

Regarding the basic characteristics of the 38 participants of this study, the male:female ratio was 28:10, which is consistent with the epidemiology of PFCD in China, but different from that in Europe and the USA [25]. The proportion of smokers was only 5.3%, which is much lower than that in Western countries. The family history of IBD was 0%, which may be due to the low incidence and low detection rate of the condition in China 10 years ago. Other basic patient information was similar to that in research in China and abroad.

Published studies on the efficacy of IFX therapy for PFCD as evaluated by MRI are summarized in Table 4 [13, 25–28]. The clinical and deep remission rates observed in this study were higher than those presented in Table 4. The reasons are as follows.

First, not all patients in earlier studies were naïve to anti-TNF agents. Several patients had refractory PFCD that had already failed to respond to other anti-TNF agents. Despite the similar efficacy of each anti-TNF agent, the use of a second anti-TNF agent is often not as effective as that of the initial anti-TNF agent, but it is still effective in some patients [26]. Currently, of the anti-TNF drugs available for the treatment of CD, only IFX is approved in China. All patients in this study were naïve to IFX. A retrospective study of patients naïve to adalimumab therapy showed that 39% of patients achieved radiologic remission after 6 months [22] —a higher proportion than those of the five studies listed in Table 4 in which patients were not naïve to IFX.

Second, the patients studied in the papers listed in Table 4 were Europeans and Americans, whereas the patients enrolled in this study were Han Chinese. It has been shown that the expression of five genes (S100A8, S100A9, G0S2, TNFAIP6 and IL11) has an etiologic role in the IFX response pathway and predicts the response to IFX of patients with CD [29]. However, the
The susceptibility genes of CD differ between Chinese and Western patients. It can be inferred from the results of this study that the efficacy of IFX for PFCD is better in Chinese patients than in Western patients.

Third, studies have shown that the shorter the disease duration, the higher the response rate to biologic agents [30, 31]. A retrospective study with a small sample size showed that patients with PFCD with disease durations (before the beginning of anti-TNF treatment) of less than 3, 3–6 and >6 years achieved radiographic healing rates of 50, 38 and 14%, respectively [26]. The average disease duration in this study was 1.95 ± 3.01 years—well below those of the five studies presented in Table 4.

Fourth, in this study, 68.4% of the patients had complex fistulas and 5.3% had anorecto-vaginal fistulas—well below the proportions of patients with these conditions in the studies listed in Table 4. In combination with the fact that several patients had already failed to respond to other anti-TNF agents, the PFCD described in those papers presented in Table 4 was more refractory than that described in this study. Furthermore, the number of fistulas was a risk factor for no response to IFX therapy in patients with PFCD [13].

IFX is safe and efficient for the treatment of PFCD. However, treatment options for PFCD are limited and biologics are expensive. Consequently, it is important to explore the predictors of treatment response. In the first study listed in Table 4, 33% of patients achieved deep remission 2 years after receiving anti-TNF agents and the absence of rectal involvement on MRI was the only predictor of deep remission [25]. Other studies in Table 4 showed that a large number of fistulas [13] and proctitis [26, 27] are risk factors for no response to IFX. Another study showed that proctitis is a predictor of poor response and even proctectomy [32]. In addition, a single-center study showed that a history of perianal abscesses and antibiotic treatment in the course of anti-TNF therapy were predictors of poor response in PFCD [33]. Moreover, individuals with a younger age at onset, male sex, rectal lesions and non-white or Jewish ethnicities were at high risk of developing perianal lesions [8, 34]. However, our study indicated that the only predictor of deep remission was simple anal fistula.

One study showed that an aggregate length of ≥2.5 cm predicted disease progression, whereas a maximum single fistula length of <2.5 cm on MRI predicted treatment response; thus, the authors recommended that the measurement of fistula length should be incorporated into routine clinical practice [35]. We measured both the length and diameter of the main fistula using MRI. Unfortunately, neither the length nor the diameter of the main fistula was a risk factor in univariate or multivariate analyses.

In the current study, only 21.1% of the patients were treated with a combination of IFX and AZA in this study (lower than the

### Table 4. Previous studies on the radiologic evaluation of infliximab efficacy

| Reference   | Publication year and type | Treatment No. of patients | Complex fistulas | Duration, year | Follow-up, months | Outcome | Risk factors |
|-------------|---------------------------|----------------------------|------------------|----------------|-------------------|---------|--------------|
| Thomassin [27] | 2017, retrospective IFX/ADA and IS | 49 | – | 6 | 40 | Deep remission: 33% | Rectal involvement |
| Tozer [13] | 2012, retrospective IFX and TP | 32 | 83% | 10 | 6 | Radiologic healing: 25% | Number of fistulas |
| Ng [28] | 2009, prospective IFX/ADA or with AZA | 26 | – | 12 | 6 | Deep remission: 20% | Proctitis |
| Tougeron [29] | 2008, retrospective IFX or with IS | 26 | 69%* | 13 | 59 | Clinical remission: 42% | None |
| Karmiris [30] | 2011, retrospective IFX or with IS | 29 | 85% | 9 | 9 | Reduction of fistula number: 14% | |

*Anorecto-vaginal fistula: 30%. IFX, infliximab; ADA, adalimumab; TP, thiopurine; IS, immunosuppressants; AZA, azathioprine.
proportions in the studies listed in Table 4): the rest were treated with IFX alone. A study demonstrated that AZA maximizes the long-term effects of antibiotics [36]. Similarly, studies on IFX in combination with thiopurines have shown that thiopurines increase the extent and duration of the response to IFX [37, 38]. The European Evidence-Based Consensus on the Diagnosis and Management of Crohn’s Disease 2016 stated that combination of anti-TNF treatment with thiopurines may enhance the effects of anti-TNF agents on complex fistulizing disease [39]. However, some studies asserted that IFX alone achieves better outcomes than in combination with AZA. It was inferred from the subgroups of the ACCENT I and II trials that the use of IFX in combination with ISs does not increase its efficacy or pharmacokinetics [40]. In addition, a randomized controlled study showed that the mucosal healing of the combination of IFX and ISs was not statistically superior to IFX alone after continuous treatment for 6 months [41]. Another retrospective study showed that the improvement rates in MRI findings of IFX alone and IFX in combination with ISs at 12 months were 53 and 67%, respectively [26]. Therefore, whether the combination of IFX and AZA is superior to IFX alone is inconclusive. However, in current clinical practice in China, monotherapy is preferable. First, Chinese patients have better response to biologic agents. Second, Chinese patients have more side effects when receiving combination of IFX and AZA.

Currently, Van Assche score is widely used in clinical research [20]. However, our findings suggest that this score has some limitations related to its inability to reflect new fistulas and abscesses in some circumstances [42]. For example, when a third fistula emerges when two initial fistulas are unchanged, Van Assche score remains unchanged because of the invariability of the complexity of the fistula tracks. In this case, Van Assche score no longer reflects the deterioration of the disease, and vice versa when one of the three initial fistulas heals. Also, when the original abscess lesion turns into granulation tissue, Van Assche score does not show any improvement. In order to better reflect the changes evident on imaging, a more standard, effective and uniform grading standard needs to be developed. Hence, in this study, we used Ng score to compare the changes between the initial and follow-up MRIs in each patient, which is more objective and suitable for monitoring the therapeutic effect.

In this study, the consistency of the clinical and radiologic evaluations was high. Fistula closure is often later on MRI than on clinical evaluation. When the fistula has not yet fully undergone fibrosis and closure of the external orifice, there is a risk of recurrence. Therefore, pelvic enhancement MRI is essential for monitoring the therapeutic effect.

In conclusion, IFX is safe and effective for PFCD with a high deep remission rate. The only predictor of deep remission is simple fistula. MRI is the gold standard for evaluating PFCD, but Van Assche score has some limitations.

Funding
This work was supported by the National Natural Science Foundation of China (No. 81302092, 81302095 and 81600435), the Fundamental Research Funds for the Central Universities (No. YG2015QN38) and the Foundation for Fostering Clinical Research of Renji Hospital (No. PYMDT-005).

Acknowledgements
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Research Ethics Committee of Renji Hospital (School of Medicine, Shanghai Jiao Tong University, Shanghai, China) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Supplementary Data
Supplementary data is available at Gastroenterology Report online.

Conflict of interest statement: none declared.

References
1. Maconi G, Gridavilla D, Vigano C. Perianal disease is associated with psychiatric co-morbidity in Crohn’s disease in remission. Int J Colorectal Dis 2014;29:1285–90.
2. Beaugerie L, Seksik P, Nion-Larmurier I et al. Predictors of Crohn’s disease. Gastroenterology 2006;130:650–6.
3. Hellers G, Bergstrand O, Ewerth S et al. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980;21:525–7.
4. Schwartz DA, Loftus EV, Tremaine WJ et al. Response to infliximab in Crohn’s disease: genetic analysis supporting expression profile the natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–80.
5. Tang LY, Rawsthorne P, Bernstein CN. Are perianal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 2006;4:1130–4.
6. Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn’s disease. Gut 1995;37:696–701.
7. Molendijk I, Nuij VJ, van der Meulen-Jong AE et al. Disappearing durable remission rates in complex Crohn’s disease fistula. Inflamm Bowel Dis 2014;20:2022–8.
8. Marzo M, Felice C, Pugliese D et al. Management of perianal fistulas in Crohn’s disease: an up-to-date review. World J Gastroenterol 2015;21:1394–403.
9. Juncadella AC, Alame AM, Sands LR et al. Perianal Crohn’s disease: a review. Postgrad Med 2015;127:266–72.
10. Ran Z. Diagnosis and Treatment Strategy of Inflammatory Bowel Disease. Shanghai: Chinese Science Press, 2015.
11. Lightner AL, Shen B. Perioperative use of immunosuppressive medication in patients with Crohn’s disease in the new ‘biological era’. Gastroenterol Rep (Oxf) 2017;5:165–77.
12. Ingle SB, Loftus EV Jr. The natural history of perianal Crohn’s disease. Dig Liver Dis 2007;39:963–9.
13. Tozer P, Ng SC, Siddiqui MR et al. Long-term MRI-guided combined anti-TNF-alpha and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis 2012;18:1825–34.
14. Gecse KB, Bemelman W, Kamm MA et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014;63:1381–92.
15. Van Assche G, Dignass A, Reinisch W et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis 2010;4:63–101.
16. Gecse KB, Sebastian S, Hertogh G et al. Results of the fifth scientific workshop of the ECCO (II): clinical aspects of perianal fistulising Crohn’s disease—the unmet needs. J Crohns Colitis 2016;10:758–65.
17. Best WR, Becktel JM, Singleton JW et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70:439–44.
18. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index: McMaster IBD Study Group. J Clin Gastroenterol 1995;20:27–32.
19. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–405.
20. Van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003;98:332–9.
21. Ng SC, Flamondon S, Gupta A et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas. Aliment Pharm Ther 2009;30:757–66.
22. Castaño-Milla C, Chaparro M, Saro C et al. Effectiveness of adalimumab in perianal fistulas in crohn’s disease patients naive to anti-TNF therapy. J Clin Gastroenterol 2015;49:34–40.
23. Hanauer SB, Feagan BG, Lichtenstein GR, ACCENT I Study Group et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541–9.
24. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–85.
25. Thomassín I, Armengol-Debeir L, Charpentier C et al. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn’s disease. World J Gastroenterol 2017;23:4285–92.
26. Ng SC, Flamondon S, Gupta A et al. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn’s perineal fistulas. Am J Gastroenterol 2009;104:2973–86.
27. Tougeron D, Savoye G, Savoye-Collet C et al. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn’s disease. Dig Dis Sci 2009;54:1746–52.
28. Karmiris K, Bielen D, Vanbeckevoort D et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn’s disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol 2011;9:130–6.
29. Medrano LM, Taxonera C, González-Artacho C et al. Response to Infliximab in Crohn’s disease: genetic analysis supporting expression profile. Mediators Inflamm 2015;2015:318207.
30. Kugathasan S, Welin SL, Martinez A et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn’s disease. Am J Gastroenterol 2000;95:3189–94.
31. Lionetti P, Bronzini F, Salvestrini C et al. Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 2003;18:425–31.
32. Panes J, Jairath V, Levesque BG. Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases. Gastroenterology 2017;152:362–73e363.
33. Rayen J, Currie T, G erray R B et al. The long-term outcome of anti-TNF alpha therapy in perianal Crohn’s disease. Tech Coloproctol 2017;21:119–24.
34. Tozer PJ, Burling D, Gupta A et al. Review article: medical, surgical and radiological management of perianal Crohn’s fistulas. Aliment Pharmacol Ther 2011;33:5–22.
35. Shenoy-Bhangle A, Nimkin K, Goldner D et al. MRI predictors of treatment response for perianal fistulizing Crohn disease in children and young adults. Pediatr Radiol 2014;44:23–9.
36. D e jaco C, Harrer M, Walldh oer T et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003;18:1113–20.
37. Visiedo A, Habib FI, Kohn A et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther 2003;17:1263–71.
38. Topstad DR, Panaccione R, Heine JA et al. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn’s disease: a single center experience. Dis Colon Rectum 2003;46:577–83.
39. Gionchetti P, Dignass A, Danese S et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 2: Surgical management and special situations. J Crohns Colitis 2017;11:135–49.
40. Lichtenstein GR, Diamond RH, Wagner CL et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210–26.
41. Van Assche G, Magdelaine-Beuzelin C, D’Haens G et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008;134:1861–8.
42. Korelitz BI, Adler DJ, Mendelsohn RA et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterol 1993;88:1198–205.
43. Davidov Y, Ungar B, Bar-Yoseph H et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis 2017;11:549–55.
44. Yarur AJ, Kanagala V, Stein DJ et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther 2017;45:933–40.